Variable | Group A Pioglitazone (n = 42) | Group B Other treatment (n = 39) | P value |
---|---|---|---|
Age, years (range) | 64.3 ± 8.1 (44-77) | 64.8 ± 7.5 (48-81) | 0.78 |
Female gender, n (%) | 27 (64) | 28 (72) | 0.49 |
Hypertensives, n (%) | 31 (74) | 32 (82) | 0.27 |
Hyperlipidaemics, n (%) | 26 (62) | 27 (69) | 0.64 |
Ever smokers, n (%) | 14 (33) | 10 (26) | 0.48 |
Family history of CAD | 23 (55) | 24 (62) | 0.35 |
Duration of diabetes, years | 10.2 ± 6.6 | 9.0 ± 6.9 | 0.41 |
Metformin | 31 (74) | 26 (67) | 0.63 |
Sulfonylurea | 31 (74) | 27 (69) | 0.81 |
Metformin & Sulfonylurea | 20 (48) | 15 (38) | 0.50 |
Antihypertensives, n (%) | 27 (64) | 27 (69) | 0.81 |
Diuretics, n (%) | 6 (14) | 8 (21) | 0.56 |
ACE or AT-II inhibitors, n (%) | 22 (52) | 22 (56) | 0.82 |
β-blockers, n (%) | 1 (2) | 3 (8) | 0.35 |
Calcium channel blockers, n (%) | 12 (29) | 11 (28) | 1.00 |
Statin, n (%) | 18 (43) | 17 (44) | 1.00 |
Antiplatelets, n (%) | 5 (12) | 4 (10) | 1.00 |